Abstract: An injector cartridge is configured for sterile storage and transfer of a fluid in a pre-filled syringe. The injector cartridge includes a first housing section and a second housing section and is configured to move the pre-filled syringe from a sterile storage position to a fluid transfer position upon linear displacement of the first housing section relative to the second housing section.

Abstract: An apparatus for transdermal injection includes a collet configured to transition between first and second states. In the first state, the collet receives a cartridge with a predetermined elongate shape. In the second state, an inner surface of the collet substantially conforms to the predetermined elongate shape of the cartridge such that expansion of the cartridge, when the cartridge is pressurized, is substantially uniformly opposed.

Abstract: An adapter for use with an injection device includes a first end, a second end and a first longitudinal axis extending from the first end and the second end. The adapter also includes a chamber defined by a sidewall between the first end and second end and a nozzle having a passageway extending through the sidewall, the passageway having an input at the chamber, an output at an outer surface of the body and a passageway axis extending from the input to the output, the passageway axis being angularly offset from the longitudinal axis of the channel. A cartridge can include such an adapter.

Abstract: An apparatus for transdermal injection includes a sleeve including a proximal end, a distal end, and an inner wall surface extending along the sleeve from a first opening at the proximal end to a second opening at the distal end. The inner wall surface forms a channel in the sleeve, the channel having a first portion with a substantially frustoconical shape. The channel of the sleeve is configured to receive a substantially frustconically shaped injection cartridge, to substantially uniformly support the injection cartridge during a transdermal injection operation, and to prevent movement of the injection cartridge out of the distal end of the sleeve.

Abstract: Needle-less extraction of a biospecimen from tissue having a number of tissue layers including an epidermis layer includes creating a first port through a target surface and into an underlying one of the tissue layers, creating a second port through the target surface and into the underlying one of tissue layers, providing an injectate through the first port to the underlying one of the tissue layers underlying the epidermis layer, and extracting at least a portion of the injectate and the biospecimen from the underlying one of the layers through the second port.

Abstract: An apparatus for use in injectate delivery includes an actuator including a linkage, a force generating mechanism mechanically coupled to the linkage, and a controller coupled to the force generating mechanism. The force generating mechanism includes a passive force generator and an active force generator. In operation and on the basis of a control signal, the controller is configured to control the force generating mechanism to provide an input force to the linkage that is a combination of the first force provided by the passive force generator and a second force provided by the active force generator.

Abstract: An injection device for use with a cartridge facilities a transfer of fluid from the cartridge into an injection bore.

Abstract: An injectate delivery device for expanding tissue is provided. The injectate delivery device comprises: at least one fluid delivery tube comprising a proximal end, a distal end and a lumen therebetween; at least one fluid delivery element in fluid communication with the at least one fluid delivery tube lumen; a radially expanding element comprising the at least one fluid delivery element; a supply of vacuum constructed and arranged to cause tissue to tend toward the at least one fluid delivery element; and at least one control constructed and arranged to perform a function. The at least one control can be constructed and arranged to expand the radially expandable element and activate the supply of vacuum. Systems and method of injectate delivery are also provided.

Abstract: A drug or medical treatment dispenser comprises a tube having a plurality of apertures from which a treatment is spayed towards the skin of a person or animal.

Abstract: A needle free injection device for use with a cartridge containing an injectate includes a housing. The housing includes an end wall at its distal end and an inner wall. The inner wall extends in a direction from the proximal end of the housing to the distal end of the housing and separates a first chamber from a second chamber in the housing. The housing includes a first opening disposed in the end wall and is in fluid communication with the first chamber. The housing includes a second opening is in fluid communication with the second chamber. A coupler is disposed in the first chamber for coupling to the cartridge. The first opening and the second opening are in fluid communication via a channel for transfer of fluid between the first chamber and the second chamber.

Abstract: A device for ablating target tissue of a patient with an ablative fluid is provided. An elongate shaft includes a proximal portion and a distal portion, and at least one fluid delivery element is attached to the distal portion. The device can be configured to ablate the duodenal mucosa of a patient while avoiding damage to the duodenal adventitial tissue. Systems and methods of treating target tissue are also provided.

Abstract: A device for expanding tissue comprises at least one fluid delivery tube and at least one fluid delivery element in fluid communication with the at least one fluid delivery tube. The at least one fluid delivery tube comprises a proximal end, a distal end, and a lumen therebetween. The device is constructed and arranged to perform a near full circumferential expansion of luminal wall tissue. Systems and methods are also provided, including a system for expanding tissue layers and treating tissue proximate to the expanded tissue layers.

Abstract: A system for treatment target tissue comprises an ablation device and an energy delivery unit. The ablation device comprises an elongate tube with an expandable treatment element. The system delivers a thermal dose of energy to treat the target tissue. Methods of treating target tissue are also provided.

Abstract: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.

Abstract: The present invention relates to a method of treating a cachexia and/or sarcopenia with an oral dose of S-pindolol or a pharmaceutical formulation thereof and to an oral formulation for use in said method of treatment. The method and oral formulation comprise administering a total daily dose of 2.5 to 20 mg of S-pindolol or a pharmaceutical formulation comprising the same.

Abstract: The present application is directed to devices. The device may used for connecting a closed receptacle and a container, such as a syringe.

Abstract: A coffee maker with continuously adjustable water flow rate, continuously adjustable feedback-controlled water temperature, and low thermal mass allows baristas to experiment with and digitally program and/or record different flow-rate and temperature profiles (brewing profiles) over the course of brewing a cup or batch of coffee. Brewing profiles may be recorded on one machine and reproduced (played back) on another machine, allowing reproducibility of subtle flavor variations in brewed coffee.

Abstract: The present invention provides a means for prevention and treatment of sarcopenia by administration of a substance that both reduces the sensibility of beta-adrenergic receptors and of 5-HT1a receptors. (S)-pindolol, (S)-propanol, tertalol, or bopindolol are preferred for this purpose.

Abstract: A method of treating, preventing or ameliorating chronic heart failure or acute heart failure in a patient the method comprising administering to the patient an effective amount of: a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule, for example LPS binding protein, BPI, lipoproteins, bile acids or an antibody capable of binding LPS, a compound that is able to bind to an endotoxin (lipopolysaccharide; LPS) molecule or bacterium in the gut, for example charcoal, a bile acid or Fuller's earth, an antibacterial agent that is substantially active in the gut, an agent that is able to inhibit the response by a cell to endotoxin (lipopolysaccharide; LPS), an agent that may form a barrier or that otherwise impedes translocation of bacteria or endotoxin (LPS) from the gut into the patient's circulation.

Abstract: A method for treating cachecia, liver disease, and other wasting syndromes is provided. The treatment method comprises administering a therapeutically effective amount of a compound that is able to reduce the production, absorption and/or the effect of an endotoxin. Examples of such compounds include, but are not limited to, bile acids; bactericidal/permeability increasing proteins; lipoproteins; antibodies capable of binding to endotoxins; LPS binding protein; activated charcoal, Fuller's earth, attapulgite, kaolin or bentonite or a clay; a drug blocking effectively signaling through toll-like receptors; and calostrum or human, bovine or other mammals.